This company has been marked as potentially delisted and may not be actively trading. Intensity Therapeutics, Inc. Common stock (INTS) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesOwnershipShort InterestTrendsBuy This Stock Get the Latest News and Ratings for INTS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Intensity Therapeutics, Inc. Common stock and its competitors. Enter your email to sign up for newsletter Sign Up INTS Analyst Ratings Over TimeTypeCurrent Forecast5/22/24 to 5/22/251 Month Ago4/22/24 to 4/22/253 Months Ago2/22/24 to 2/21/251 Year Ago5/23/23 to 5/22/24Strong Buy0 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)0 Strong Buy rating(s)Buy3 Buy rating(s)3 Buy rating(s)3 Buy rating(s)1 Buy rating(s)Hold1 Hold rating(s)0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$8.50$8.50$8.50$12.00Forecasted Upside2,241.60% Upside359.21% Upside282.02% Upside139.52% UpsideConsensus RatingModerate BuyBuyBuyBuy INTS Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History INTS Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Intensity Therapeutics, Inc. Common stock Stock vs. The CompetitionTypeIntensity Therapeutics, Inc. Common stockMedical CompaniesS&P 500Consensus Rating Score 2.75 2.81 2.54Consensus RatingModerate BuyModerate BuyModerate BuyPredicted Upside2,261.11% Upside5,064.31% Upside16.24% UpsideNews Sentiment RatingVery Positive NewsSee Recent INTS NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails5/19/2025Brookline Capital Management3 of 5 starsK. RajaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold1/13/2025Alliance Global Partners1 of 5 starsJames MolloySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.50+295.81%11/21/2024HC Wainwright1 of 5 starsS. RamakanthSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00+69.49%7/11/2024BenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingR. WassermanSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$12.00 ➝ $12.00+144.90%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 04:17 PM ET. INTS Forecast - Frequently Asked Questions What is Intensity Therapeutics, Inc. Common stock's forecast for 2025? According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Intensity Therapeutics, Inc. Common stock is $8.50, with a high forecast of $12.00 and a low forecast of $5.00. Should I buy or sell Intensity Therapeutics, Inc. Common stock stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intensity Therapeutics, Inc. Common stock in the last twelve months. There is currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" INTS shares. Does Intensity Therapeutics, Inc. Common stock's stock price have much upside? According to analysts, Intensity Therapeutics, Inc. Common stock's stock has a predicted upside of 2,241.60% based on their 12-month stock forecasts. Has Intensity Therapeutics, Inc. Common stock been downgraded by Wall Street analysts recently? Over the previous 90 days, Intensity Therapeutics, Inc. Common stock's stock had 1 downgrade by analysts. What analysts cover Intensity Therapeutics, Inc. Common stock? Intensity Therapeutics, Inc. Common stock has been rated by research analysts at Brookline Capital Management in the past 90 days. Do Wall Street analysts like Intensity Therapeutics, Inc. Common stock more than its competitors? Analysts like Intensity Therapeutics, Inc. Common stock less than other "medical" companies. The consensus rating score for Intensity Therapeutics, Inc. Common stock is 2.75 while the average consensus rating score for "medical" companies is 2.81. Learn more on how INTS compares to other companies. Stock Forecasts and Research Tools Related Companies Protalix BioTherapeutics Stock Forecast Compugen Stock Forecast Editas Medicine Stock Forecast Protara Therapeutics Stock Forecast Vigil Neuroscience Stock Forecast Fate Therapeutics Stock Forecast Alpha Cognition Stock Forecast Alector Stock Forecast Invivyd Stock Forecast Neumora Therapeutics Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:INTS) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intensity Therapeutics, Inc. Common stock Please log in to your account or sign up in order to add this asset to your watchlist. Share Intensity Therapeutics, Inc. Common stock With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
